Treatment of candidal infections with fluconazole in neonates and infants.

摘要: UNLABELLED To study the therapy, efficacy and safety of fluconazole in candidal mycoses during neonatal phase infancy a case review 53 newborns infants was performed. The majority these patients were premature with median birth weight 1120 g born within gestational week 23-38. age at onset treatment 5 weeks. All had underlying diseases several risk factors, which favored occurence systemic mycosis. Systemic candidiasis most frequent diagnosis (75.5%). Fluconazole administered daily dosage 5-6 mg/kg for duration 21 days. hepatic, renal hematologic functions assessed before, one, two, three weeks after start treatment. Yeasts identified 37 patients. common fungus isolated baseline Candida albicans (68%). Clinical cure or improvement reported 31 out 38 (81.6%). Mycological achieved 25 32 infants. Despite limited number outcome data, preliminary results small cohort clearly indicate effective antifungal therapy neonates No serious side effects observed fluconazole-treated Two megaureter-megacystis-hydronephrosis syndrome severe meningoencephalitis showed mild increase liver enzymes. - CONCLUSION seems to be an other forms including very low (VLBWI; <1500 g). These favorable data are similar obtained older children adults. findings, however, must supported by larger trials. recommended dose is body weight. Only VLBWI interval first two life should prolonged up 3 days serum levels monitored.